The efficacy and safety of magnetic resonance imaging-guided high intensity focused ultrasound (MRg-HIFU) treatment of intermediate risk prostate cancer is being assessed as part of a clinical trial. Non-perfused volume (NPV) on post-treatment contrast-enhanced imaging defines the zone of ablation, however contrast administration precludes further treatment due to concern for gadolinium dissociation. Thus, pre-contrast imaging tools which can predict NPV are of value. From a cohort of 19 men who underwent MFg-HIFU for treatment of prostate cancer, we show that post-treatment DWI can predict NPV, with the potential to increase confidence in predicting the ablation zone prior to contrast administration.
This abstract and the presentation materials are available to members only; a login is required.